ClearPoint Neuro Inc (NASDAQ:CLPT) reported first-quarter financial results after the market close on Tuesday. Here’s a rundown of the report.
Q1 Earnings: ClearPoint Neuro, a device, cell and gene therapy-enabling company, reported first-quarter revenue of $8.4 million, beating analyst estimates of $8.2 million. The company reported a first-quarter loss of 22 cents per share, missing estimates for a loss of 16 cents per share, according to Benzinga Pro.
Total revenue was up 11% year-over-year as total consumable product revenue jumped 104%. Here’s a breakdown of revenue by category:
ClearPoint Neuro reported total operating expenses of $11.3 million in the quarter. The company ended the period with $12.4 million in cash and cash equivalents.
“Our 2025 fiscal year is off to a strong start as we enter the Fast Forward phase of the company, starting with a record revenue quarter and fueled by multiple new product launches that are delivering on our promise of fast, simple and predictable procedures,” said Joe Burnett, president and CEO of ClearPoint Neuro.
“The foundational investments that we have made over the past few years to grow our global biopharma partnerships, expand navigation into the operating room, and enter the laser therapy market are now paying off and are underlined by 104% growth in these single-use devices.”
Outlook: ClearPoint Neuro affirmed its full-year 2025 sales guidance of $36 million to $41 million versus estimates of $38.23 million.
ClearPoint executives are currently discussing the quarter on a conference call that kicked off at 4:30 p.m. ET.
CLPT Price Action: ClearPoint Neuro shares were up 1.76% after-hours, trading at $14.45 at the time of publication Tueday, according to Benzinga Pro.
Read Next:
Photo: Shutterstock.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。